Loading...
•
Jun 30, 2022
Mirum Pharmaceuticals Q2 2022 Earnings Report
Reported financial results for the second quarter ended June 30, 2022 and provided a business update.
Key Takeaways
Mirum Pharmaceuticals reported net product sales revenue of LIVMARLI for the quarter ended June 30, 2022 was $17.5 million. The company reported a net loss of $26.9 million, or $0.84 net loss per share. As of June 30, 2022, Mirum had cash, cash equivalents, restricted cash equivalents and investments of $225.0 million.
Net product sales for LIVMARLI totaled $17.5 million in the second quarter of 2022.
Total operating expenses for the quarter ended June 30, 2022 were $48.9 million.
For the quarter ended June 30, 2022, Mirum reported a net loss of $26.9 million, or $0.84 net loss per share.
As of June 30, 2022, Mirum had cash, cash equivalents, restricted cash equivalents and investments of $225.0 million.
Mirum Pharmaceuticals
Mirum Pharmaceuticals
Forward Guidance
Mirum expects a strong finish to 2022 with topline MARCH PFIC Phase 3 data and anticipated EMA approval in Alagille syndrome by the end of the year.
Positive Outlook
- Potential approval of MAA for the treatment of cholestasis in patients with Alagille syndrome in the fourth quarter of 2022.
- Topline data evaluating more than 90 patients in the MARCH PFIC Phase 3 clinical trial in the fourth quarter of 2022.
- Topline data in the EMBARK Phase 2b clinical trial for biliary atresia in the second half of 2023.
- Interim analysis for the VISTAS Phase 2b clinical trial for primary sclerosing cholangitis in mid-2023.
- Interim analysis for the OHANA Phase 2b clinical trial for intrahepatic cholestasis of pregnancy in the first half of 2023.